Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTOG2 gemcitabine/cisplatin or gemcitabine/carboplatin for advanced NSCLC
2004-003868-30Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- May 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by University of Birmingham. Primary endpoint: Overall survival. Started May 2005; status: completed.
02
Drugs
gemcitabinecisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-003868-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003868-30.